ApoM-Fc fusion proteins, complexes thereof with sphingosine 1-phosphate (S1P), and methods for treating vascular and non-vascular diseases

Patent metadata

Field	Value
Publication number	US-10870689-B2
Application number	US-201716326089-A
Country	US
Kind code	B2
Filing date	Aug 15, 2017
Priority date	Aug 15, 2016
Publication date	Dec 22, 2020
Grant date	Dec 22, 2020

Abstract

The present disclosure is directed to an engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperone derived from an Apolipoprotein M (ApoM)-Fc fusion protein having an extended half life in vivo. The disclosed ApoM-Fc fusion protein provides a safe, efficient and effective means of delivering S1P to endothelial cells and to all tissues of the body.

First claim

What is claimed is:

1. A fusion protein comprising an Apolipoprotein M (ApoM) polypeptide fused to a fragment crystallizable (Fc) region of an antibody, wherein the ApoM polypeptide comprises amino acids 21-188 of SEQ ID NO: 9 and does not comprise amino acids 1-20 of SEQ ID NO: 9.

2. The fusion protein of claim 1 , wherein the fusion protein further comprises an IL-2 signal peptide at the amino-terminus.

3. The fusion protein of claim 1 , wherein the Fc region is fused to the amino terminus of the ApoM polypeptide.

4. The fusion protein of claim 2 , wherein the Fc region is fused to the carboxyl terminus of the ApoM polypeptide.

5. The fusion protein of claim 1 , wherein the Fc region is an Fc region selected from the group consisting of an IgG antibody, an IgM antibody, an IgA antibody, an IgE antibody, and an IgD antibody.

6. The fusion protein of claim 5 , wherein the Fc region is an IgG1-Fc.

7. A composition comprising the fusion protein of claim 1 in complex with phospholipids or lysophospholipids.

8. The composition of claim 7 , wherein the phospholipids comprise phosphocholine.

9. The composition of claim 7 , wherein the phospholipids comprise sphingosine 1-phosphate (S1P).

10. The composition of claim 7 , wherein the composition is formed by mixing the fusion protein with the phospholipids or the lysophospholipids, incubating the mixture to allow the complex to form, and purifying the complex.

11. The composition of claim 10 , wherein the phospholipids comprise phosphocholine.

12. The composition of claim 10 , wherein the phospholipids comprise sphingosine 1-phosphate (S1P).

13. A method of treating a condition in a subject, comprising administering a composition according to claim 9 to the subject, wherein said condition is selected from the group consisting of hypertension, ischemia of the heart, ischemia of the brain, accelerated atherosclerosis, non-cardiac reperfusion injury and peripheral vascular disease.

14. The method of claim 13 , wherein said hypertension comprises conditions selected from the group consisting of primary resistant hypertension, secondary resistant hypertension, neurogenic hypertension, gestational hypertension (pre-eclempsia), diabetic pre-eclempsia, and hypertension of chronic kidney disease.

15. The method of claim 13 , wherein said ischemia of the heart comprises diseases selected from the group consisting of cardiac reperfusion injury, myocardial infarction, acute coronary syndrome and angina.

16. The method of claim 13 , wherein said non-cardiac reperfusion injury comprises an injury as a result of an ischemia selected from the group consisting of liver ischemia, kidney ischemia, intestinal ischemia, and muscle ischemia.

17. A method of reducing a side effect of Fingolimod in a patient being treated with Fingolimod comprising administering the ApoM-Fc fusion protein of claim 1 to the patient.

Assignees

• Childrens Medical Center
• Childrens Medical Ct Corp

Inventors

• Hla Timothy T
• Swendeman Steven L
• Dilorenzo Annarita
• Sanchez Teresa

Classifications

• C07K19/00

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

• A61P9/02

  Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives · CPC title

• A61K38/1709

  from mammals · CPC title

• A61K8/553

  Phospholipids, e.g. lecithin · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title